Observational studyEuropean journal of haematology2022

Ibrutinib as a treatment of hematologic autoimmune disorders in patients with indolent B-cell lymphoma.

Adrien Daniel et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.